Summit Therapeutics partners with AstraZeneca and Daiichi Sankyo on cancer trial; Eccogene hits $50 million milestone
read at Endpoints ↗DealPositive
Summit Therapeutics announced a partnership with AstraZeneca and Daiichi Sankyo to evaluate its Trop-2‑directed antibody‑drug conjugate in a clinical trial.
The collaboration will involve joint development and testing of the cancer candidate, leveraging the partners' expertise and resources.
Separately, Eccogene reported receiving a $50 million milestone payment, reflecting progress in its development program.
The briefing also mentioned additional news about Regeneron, though no further details were provided.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone”
read at Endpoints ↗75 words · retrieved 2h ago
comments(0)
5-min edit window · permanent after that